FDA Approval and Cleared Indications
Skinvive's 510(k) pathway (rather than a full PMA) reflects its classification as a low-to-moderate-risk device with substantial equivalence to existing HA fillers. The approval specifically covers:
- Cheeks (for improvement of skin quality and appearance)
- Neck (for skin quality improvement)
The indication is narrower than Juvéderm's volume-based products (Ultra, Voluma, Volbella). Skinvive is cleared for intradermal placement only, not subcutaneous or supraperiosteal injection, which is central to its mechanism and safety profile.
Microdroplet Technology and Formulation
Skinvive's differentiation lies in its microdroplet architecture. The product is a 10 mg/mL HA formulation engineered for superficial intradermal deposition in small aliquots (0.1 mL per injection point). This contrasts sharply with traditional fillers, which use larger volumes and deeper placement for structural support.
The microdroplet approach creates a lattice-like hydration and structural support in the upper dermis, theoretically stimulating collagen remodeling and improving skin texture over time. Clinical data submitted to the FDA showed sustained improvement in skin quality scores at 12 weeks and beyond, with results building over a series of treatment sessions (typically 3 sessions, 2 weeks apart).
Clinical Positioning and Practice Economics
For practice owners, Skinvive represents a new revenue stream distinct from traditional filler and neurotoxin offerings. It appeals to patients seeking non-invasive skin quality improvement without the commitment or downtime of laser or RF microneedling. Pricing typically ranges from $600–$800 per treatment session, with a standard course requiring 3 sessions.
The product is supplied through Allergan Aesthetics' Alle loyalty program, so rebate structures and volume incentives apply similarly to other Juvéderm products. Skinvive does not require special credentialing beyond standard filler injection training, though intradermal technique precision is critical for optimal results.
Important Regulatory Notes
Skinvive's approval is specific to the cheeks and neck. Off-label use in other anatomies (hands, décolletage, etc.) is legally permissible but falls outside the cleared indication and carries different liability and informed-consent implications. Always verify current FDA status and labeling with Allergan Aesthetics or the FDA directly, as regulatory guidance can evolve.
Frequently asked questions
Is Skinvive by Juvéderm FDA approved?
Yes, Skinvive received FDA 510(k) clearance in September 2023. It is the first and only hyaluronic acid filler approved specifically for improving skin quality and texture in the cheeks and neck through intradermal microdroplet injection, not for volume restoration.
What is the difference between Skinvive and other Juvéderm fillers?
Skinvive is designed for skin quality improvement in the superficial dermis, while products like Juvéderm Ultra, Voluma, and Volbella are approved for volume restoration and facial contouring at deeper layers. Skinvive uses a 10 mg/mL microdroplet formulation injected intradermally in small 0.1 mL aliquots, creating a lattice-like hydration effect rather than structural support.
How many Skinvive treatments do patients need?
A standard course typically requires 3 treatment sessions spaced 2 weeks apart. Clinical data showed sustained improvement in skin quality scores at 12 weeks and beyond, with results building progressively through the series.
How much does Skinvive cost per treatment?
Skinvive pricing typically ranges from $600–$800 per treatment session. A full course of 3 sessions would cost $1,800–$2,400 before any loyalty program rebates through Allergan Aesthetics' Alle program.
Can Skinvive be used off-label on hands or décolletage?
Off-label use in areas outside the cleared cheeks and neck indication is legally permissible but falls outside FDA approval and carries different liability and informed-consent implications. Always document off-label use clearly and obtain explicit patient consent.
What injection technique is required for Skinvive?
Skinvive must be injected intradermally only, not subcutaneously or supraperiosteal, which is central to its mechanism and safety profile. Intradermal technique precision is critical for optimal results, though no special credentialing beyond standard filler injection training is required.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
